http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Hossein Jadvar (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Treatment Response Assessment of Skeletal Metastases in Prostate Cancer with 18F-NaF PET/CT
Erik M. Velez,Bhushan Desai,Hossein Jadvar 대한핵의학회 2019 핵의학 분자영상 Vol.53 No.4
Purpose To determine the utility of 18F-sodium fluoride positron emission tomography-computed tomography (18F-NaF PET/ CT) in the imaging assessment of therapy response in men with osseous-only metastatic prostate cancer. Methods In this Institutional Review Board–approved single institution retrospective investigation, we evaluated 21 18F-NaF PET/CTscans performed in 14 patients with osseous metastatic disease from prostate cancer and no evidence of locally recurrent or soft-tissue metastatic disease who received chemohormonal therapy. Imaging-based qualitative and semi-quantitative parameters were defined and compared with changes in serum PSA level. Results Qualitative and semi-quantitative image-based assessments demonstrated > 80% concordance with good correlation (SUVmax κ = 0.71, SUVavg κ = 0.62, SUVsum κ = 0.62). Moderate correlation (κ = 0.43) was found between SUVmax and PSA-based treatment response assessments. There was no statistically significant correlation between PSA-based disease progression and semi-quantitative parameters. Qualitative imaging assessment was moderately correlated (κ = 0.52) with PSA in distinguishing responders and non-responders. Conclusion 18F-NaF PET/CT is complementary to biochemical monitoring in patients with bone-only metastases from prostate cancer which can be helpful in subsequent treatment management decisions.
-
Management Impact of 68Ga-DOTATATE PET/CT in Neuroendocrine Tumors
Redmond-Craig Anderson,Erik M. Velez,Bhushan Desai,Hossein Jadvar 대한핵의학회 2021 핵의학 분자영상 Vol.55 No.1
Purpose The goal of our retrospective single tertiary academic medical center investigation was to examine the added diagnostic value and clinical impact of 68Ga-DOTATATE PET/CT in the therapeutic management of patients with neuroendocrine tumors (NETs). Methods Imaging database was queried for all “PET-DOTATATE” examinations performed at our tertiary care academic institution usingMONTAGE™. The patient’s clinical history and recent prior imaging were reviewed. The additional diagnostic value and clinical management impact of 68Ga-DOTATATE were assessed through retrospective chart review. Results A total of 81 68Ga-DOTATATE PET/CT scans in 74 patients were found, and 11 patientswere excluded fromanalysis as they had no prior imaging available for comparison, with resultant analysis cohort of 63 patients. Six patients had 2 ormore 68Ga- DOTATATE PET/CT examinations. The most common primary diagnosis was undifferentiated NET (63.5%), followed by carcinoid (27.0%), paraganglioma (4.8%), insulinoma (3.2%), and pheochromocytoma (1.6%). The primary sites of disease from the most to the least common were the pancreas (36.5%), small bowel (22.2%), unknown primary (15.9%), lung (6.3%), large bowel (6.3%), and mesentery (4.8%), and other locations accounted for 7.9%. In patients who had prior imaging available for comparison, there were new lesions identified on 68Ga-DOTATATE PET/CT in 21 patients (33.3%) that were not identified on other prior imaging modalities. Of these patients, 5 underwent subsequentMRI and 1 had a repeat 68Ga-DOTATATE PET/CT to further characterize new lesions seen. Moreover, 15 patients (23.8%) had a change in treatment plan, including altering medical therapy in 9 patients, change in planned extent of surgical management in 5 patients, and cancelation of a planned primary tumor resection in 1 patient with metastatic disease. Conclusion Our retrospective cohort demonstrated that 68Ga-DOTATATE PET/CT improves lesion detection over conventional imaging in 33.3% and impacts the therapeutic management in 23.8% of patients with NET.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
